Regulatory News FDA final guidance on psychedelics opens the door to psycho-oncology researchGuidance permits treatment without psychotherapy, alarming scientists, advocates July 17, 2026Vol.52 No.28By Sara Willa Ernst
Cancer Policy House Energy & Commerce hearing focuses on America’s leadership in biomedical research, examines FDA role July 17, 2026Vol.52 No.28By Claire Marie Porter
Drugs & Targets FDA approves Padcev + Keytruda for muscle-invasive bladder cancer regardless of cisplatin eligibility July 17, 2026Vol.52 No.28
Drugs & Targets FDA approves Revtorpyk for HR+/HER2-, PIK3CA wild-type, locally advanced or metastatic breast cancer July 17, 2026Vol.52 No.28
Drugs & Targets FDA approves Sarclisa Escena for subcutaneous injection for multiple indications in MM July 17, 2026Vol.52 No.28
Drugs & Targets FDA approves companion diagnostic for Opdivo for ESCC and GEJ, gastric, and esophageal adenocarcinoma July 17, 2026Vol.52 No.28
Drugs & Targets FDA issues CRL for rivoceranib + camrelizumab as a first-line treatment for unresectable or metastatic HCC July 17, 2026Vol.52 No.28
Cancer Policy FDA halts public release of Complete Response Letters, following citizen petition July 10, 2026Vol.52 No.27By Claire Marie Porter
Cancer Policy FDA proposes rule to hold foreign tobacco companies to U.S. standards July 10, 2026Vol.52 No.27By Claire Marie Porter
Cancer Policy FDA allows ZYN nicotine pouches to make marketing claim: ZYN is safer than cigarettes July 02, 2026Vol.52 No.26By Sara Willa Ernst
